Zacks Investment Research upgraded shares of AIT Therapeutics (OTCMKTS:AITB) from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. They currently have $5.50 price objective on the stock.
According to Zacks, “AIT Therapeutics, Inc. is a clinical-stage anti-microbial therapeutic company using nitric oxide to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections, which are not effectively addressed with current standards of care. It is advancing its revolutionary respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria. AIT Therapeutics, Inc. is based in Ness Ziona, Israel. “
Separately, ValuEngine downgraded AIT Therapeutics from a buy rating to a hold rating in a research report on Wednesday, March 13th.
AIT Therapeutics (OTCMKTS:AITB) last issued its quarterly earnings data on Wednesday, February 13th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.32. Research analysts anticipate that AIT Therapeutics will post -0.78 EPS for the current year.
About AIT Therapeutics
AIT Therapeutics, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.